F/m Emerald Life Sciences Innovation ETF holds a quantitatively derived Gold Morningstar Medalist Rating. The rating reflects that it has scored particularly well on factors Morningstar research associates with future outperformance relative to category peers.
F/m Emerald Life Sciences Innovation ETF LFSC
Morningstar’s Analysis LFSC
Will LFSC outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 52.5
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Corcept Therapeutics Inc | 7.05 | 9M | Healthcare |
Travere Therapeutics Inc Ordinary Shares | 6.69 | 8M | Healthcare |
LivaNova PLC | 6.54 | 8M | Healthcare |
Cogent Biosciences Inc | 6.11 | 8M | Healthcare |
Spyre Therapeutics Inc | 5.16 | 6M | Healthcare |
BillionToOne Inc Ordinary Shares - Class A | 4.67 | 6M | Healthcare |
Guardant Health Inc | 4.41 | 5M | Healthcare |
Replimune Group Inc | 4.38 | 5M | Healthcare |
Veradermics Inc | 3.64 | 4M | Healthcare |
Mirum Pharmaceuticals Inc | 3.44 | 4M | Healthcare |